Method of inducing cardiomyocytes proliferation and treating heart diseases
AssigneeYeda Research and Development Co. Ltd.
InventorsEldad Tzahor, Elad Bassat
Life of this patent
Estimating the term…
Abstract
An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.
Claims12
A method of inducing proliferation of cardiomyocytes, the method comprising contacting the cardiomyocytes with an effective amount of an Agrin peptide which induces proliferation of the cardiomyocytes, wherein said agrin peptide is not a part of a fusion polypeptide and wherein said agrin peptide comprises a laminin G-like 1 domain (G1) and a laminin G-like 2 domain (G2).
A method of inducing proliferation of cardiomyocytes, the method comprising contacting the cardiomyocytes with an agrin peptide which inhibits the Dystroglycan complex on the cardiomyocytes wherein said agrin peptide induces proliferation of the cardiomyocytes and is not a part of a fusion polypeptide and wherein said agrin peptide comprises a laminin G-like 1 domain (G1) and a laminin G-like 2 domain (G2), thereby inducing proliferation of cardiomyocytes.
A method of treating a heart disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an agrin peptide which induces proliferation of cardiomyocytes, wherein said agrin peptide induces proliferation of the cardiomyocytes and is not a part of a fusion polypeptide and wherein said agrin peptide comprises a laminin G-like 1 domain (G1) and a laminin G-like 2 domain (G2), thereby treating the heart disease.
An implantable device comprising an agrin peptide which induces proliferation of cardiomyocytes, wherein said agrin peptide induces proliferation of the cardiomyocytes and is not a part of a fusion polypeptide and wherein said agrin peptide comprises a laminin G-like 1 domain (G1) and a laminin G-like 2 domain (G2).
Dependencies are inferred from the claim text.